Skip to main
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 20%
Buy 13%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra is well positioned for growth due to its innovative technologies in the acute care setting and expanding global market. With the recent acquisition by Boston Scientific at a premium price of $374 per share, it is evident that Penumbra is a market leader with strong revenue growth potential and a profitable business. Risks include potential competition from larger medical technology companies and unexpected liabilities or investigations.

Bears say

Penumbra is facing strong competition within the neurovascular market from competitors with significantly greater resources, such as Medtronic, Stryker, Boston Scientific, Johnson & Johnson, and Terumo. These companies offer similar products and have more resources to potentially compete with Penumbra in terms of pricing, innovation, and market reach, which could lead to a decline in sales and market share for Penumbra. Additionally, potential changes in reimbursement for neurovascular procedures could negatively impact Penumbra's business. Despite the company's commitment to creating innovative products and promoting diversity, they have not tied sustainability goals to executive compensation, which may indicate a lack of long-term strategic planning.

Penumbra (PEN) has been analyzed by 15 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 13% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Hold based on their latest research and market trends.

According to 15 analysts, Penumbra (PEN) has a Hold consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $357.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $357.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.